Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?

Angiology

Volumn 62, Issue 2, 2011, Pages 167-175

  Toms, Tracey E ^a   Panoulas, Vasileios F ^a   Douglas, Karen M J ^a   Nightingale, Peter ^b   Smith, Jacqueline P ^a   Griffiths, Helen ^c   Sattar, Naveed ^d   Symmons, Deborah P M ^e   Kitas, George D ^a,e  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c ASTON UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

cardiovascular risk; inflammation; lipid ratios; lipids; rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEFLUNOMIDE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORRELATION ANALYSIS; DENSITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; INDIVIDUALIZATION; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; RHEUMATOID ARTHRITIS; STRATIFICATION;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 78651401373     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710373749     Document Type: Article

References (47)

1. Symmons D., Turner G., Webb R., et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford). 2002 ; 41 (7). 793-800.
2. Van Doornum S., McColl G., Wicks IP Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis ? Arthritis Rheum. 2002 ; 46 (4). 862-873.
3. Pincus T., Callahan LF Taking mortality in rheumatoid arthritis seriously-predictive markers, socioeconomic status and comorbidity. J Rheumatol. 1986 ; 13 (5). 841-845.
4. Situnayake RD, Kitas G. Dyslipidemia and rheumatoid arthritis. Ann Rheum Dis. 1997 ; 56 (6). 341-342.
5. Toms TE, Symmons DP, Kitas GD Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol. 2010 ; 8 (3). 301-326.
6. Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford). 2008 ; 47 (9). 1286-1298.
7. Stevens RJ, Douglas KM, Saeatzis AN, Kitas GD Inflammation and atherosclerosis in rheumatoid arthritis. Expert rev mol med. 2005 ; 7 (7). 1-24.
8. Douglas KM, Pace AV, Treharne GJ, et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis. 2006 ; 65 (3). 348-353.
9. van Leuven SI, Franssen R., Kastelein JJ, Levi M., Stroes ES, Tak PP Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford). 2008 ; 47 (1). 3-7.
10. Parakevas KI, Mikhailidis DP C-reactive protein (CRP): more than just an innocent bystander ? Curr Med Res Opin. 2008 ; 24 (1). 75-78.
11. Khouidhunkit W., Memon RA, Feingold KR, Grunfield C. Infection and inflammation induced proatherogenic changes of lipoproteins. J Infect Dis. 2000 ; 181 (suppl 3). S462 - S472.
12. Choi HK, Seeger JD Lipid profiles among US elderly with untreated rheumatoid arthritis-the Third National Health and Nutrition Examination Survey. J Rheumatol. 2005 ; 32 (12). 2311-2316.
13. Park YB, Lee SK, Lee WK, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol. 1999 ; 26 (8). 1701-1704.
14. Peters MJ, Vis M., van Halm VP, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis. 2007 ; 66 (7). 958-961.
15. London MG, Muriden KD, Hewitt JV Serum cholesterol in rheumatic diseases. Br Med J. 1963 ; 1 (25). 1380-1383.
16. Svenson KL, Lithell H., Hallgren R., Selinus I., Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity. Arch Intern Med. 1987 ; 147 (11). 1912-1916.
17. Dursunoglu D., Evrengul H., Polat B., et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int. 2005 ; 25 (4). 241-245.
18. Rantapaa-Dahlqvist S., Wallberg-Jonsson S., Dahlen G. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis. 1991 ; 50 (6). 366-368.
19. Choy E., Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009 ; 68 (4). 460-469.
20. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 ; 285 (19). 2486-2497.
21. Department of health: National service framwork for coronary heart disease. London 2000.
22. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005 ; 91 (suppl 5). v1-52.
23. Toms TE, Panoulas VF, Douglas KMJ, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under treatment of lipid associated cardiovascular risk. Ann Rheum Dis Epub. 2009.
24. Conroy RM, Pyorala K., Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 ; 24 (11). 987-1003.
25. Sattar N., McInnes IB Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol. 2005 ; 17 (3). 286-292.
26. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 ; 31 (3). 315-324.
27. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995 ; 38 (1). 44-48.
28. Kirwan JR, Reeback JS Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol. 1986 ; 25 (2). 206-209.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 ; 28 (7). 412-419.
30. Katz A., Nambi SS, Mather K., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000 ; 85 (7). 2402-2410.
31. Traynor J., Mactier R., Geddes CC, Fox JG How to measure renal function in clinical practice. BMJ. 2006 ; 333 (7571). 733-737.
32. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A., et al. Long-term exposure to medium-dose glucocorticoid therapy assocaites with hypertension in patients with rheumatoid arthritis. Rheumatology. 2008 ; 47 (1). 72-75.
33. Stavropoulos-kalinglou A., Metsios GS, Panoulas VF, et al. Cigarette smoking associates with body weight and muscle mass of patients with rhuematoid arthritis: a cross sectional, obseravtional study. Arthritis Res Ther. 2008 ; 10 (3). R59.
34. Banks M., Flint J., Bacon PA, Kitas GD Rheumatoid arthritis is an independant risk factor for ischaemic heart disease. Arthritis Rheum. 2000 ; 43: s385.
35. Wallberg-Jonsson S., Ohman ML, Dahlqvist SR Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol. 1997 ; 24 (3). 445-451.
36. Ettinger WH, Klinefelter HF, Kwiterovitch PO Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis. 1987 ; 63 (2-3). 167-172.
37. Boers M., Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003 ; 62 (9). 842-845.
38. Ettinger WH, Goldberg AP, Applebaum-Bowden D., Hazzard WR Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med. 1987 ; 83 (3). 503-508.
39. Stern MP, Kotterman OG, Frei JF, McDevitt HO, Reaven GM Adrenocorticol steroid treatment of rheumatic diseases. Effect on lipid metabolism. Arch Intern Med. 1973 ; 132 (1). 97-101.
40. Rheumatoid arthritis: The managment of rheumatoid arthritis in adults. www.nice.org.uk/guidelines. Accessed 2009.
41. Beynen AC Can chloroquine be of value in the treatment of hypercholestrolaemia. Artery. 1986 ; 13: 340-351.
42. Munro R., Morrison E., McDonald AG, Hunter JA, Madhok R., Capell HA Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis. 1997 ; 56 (6). 374-377.
43. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med. 1990 ; 89 (3). 322-326.
44. Wierzbicki AS, Poston R., Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther. 2003 ; 99 (1). 95-112.
45. Tziomalos K., Kakafika AL, Athyros VG, Karagiannis A., Mikhailidis DP The role of statins in primary and secondary prevention of coronary heart disease in women. Curr Pharm Des. 2009 ; 15 (10). 1054-1062.
46. Kakafika A., Athyros VG, Tziomalos K., Karagiannis A., Mikhailidis DP High density lipoproein cholesterol and statin trials. Curr Med Chem. 2008 ; 15 (22). 2265-2270.
47. McCarey DW, McInnes IB, Madhok R., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double blind, randomised placebo-controlled trial. Lancet. 2004 ; 363 (9426). 2015-2021.